AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$FATE

Valamehr Bahram sold $108K of FATE

Valamehr Bahram (President and CEO) sold 43,947 shares of FATE THERAPEUTICS INC (FATE) at $2.46 ($0.11M total) on 2026-08-04.

Original reporting
SEC EDGAR · Valamehr Bahram
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FATE
Neutral
medium confidence
Mentioned
$FATE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FATENeutralLow
01

Why it matters

Bahram’s open-market sale reduces his direct share count to 591,815 shares after the transaction, but the filing does not include any company-specific operational update.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no new fundamental driver in the disclosure.

03

What to watch

The article lacks context on total compensation, tax obligations, or whether other insiders sold around the same time, which can make the signal noisy.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for FATE Therapeutics.

Company-level read

Ticker impact

$FATENeutralMedium confidence
Context

FATE Therapeutics CEO Valamehr Bahram sold 43,947 shares on 2026-08-04 for about $108.1K, per a new SEC Form 4 filing.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or additional disclosures emerge.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company performance, guidance, or regulatory/clinical event.

Market effects

Sector

Minimal; insider sale does not change biotech sector fundamentals or regulatory/clinical expectations in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales are often planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • issuer
    FATE Therapeutics Inc

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • insider
    Valamehr Bahram

    President and CEO who sold 43,947 shares at $2.4598/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FATE insider trading history →

Related articles

AUG 14
$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

finanznachrichten.de4 min
AUG 13
$FATEMed

FATE THERAPEUTICS INC (FATE): Results of Operations and Financial Condition

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated

SEC EDGAR 8-K6 min
JUL 9
$FATEMedAI 8/10

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics (NASDAQ: FATE) said the FDA cleared its IND for FT839, an off-the-shelf dual CAR T-cell candidate targeting CD19 and CD38. The company plans a Phase 1/2 multi-indication basket trial starting in 2H 2026 to test FT839 with standard-of-care for autoimmune diseases, with or without conditioning chemotherapy. Key initial indications include rheumatoid arthritis and lupus.

manilatimes.net3 min
JUL 6
$FATEMed

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics (NASDAQ: FATE) said it will present preliminary Phase 1 basket-trial data for its off-the-shelf CD19 CAR T-cell FT819 in systemic sclerosis at the ISSCR 2026 meeting (July 8–11). As of June 12, four patients showed rCRISS25+ and mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.

manilatimes.net4 min